Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 18 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed is a biopharmaceutical company with a robust commercial portfolio and promising clinical pipeline focused on respiratory, immunology, and rare neurological disorders. Despite concerns about headwinds in the near term, the company's two commercial products, Arikayce and Brinsupri, show strong demand and robust new patient starts, and management expects continued growth. With a potential market opportunity of over $10B, we believe Insmed is well-positioned to drive value for investors and its recent 1Q 2026 earnings report reinforces this positive outlook.

Bears say

Insmed is a biopharmaceutical company with a focus on respiratory, immunology, and rare neuro diseases. While the company has two approved commercial products and a robust pipeline, issues with access and adverse events are negatively impacting their success. Additionally, reliance on the success of one drug and competition in the market pose risks to their revenue potential.

Insmed (INSM) has been analyzed by 18 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Strong Buy based on their latest research and market trends.

According to 18 analysts, Insmed (INSM) has a Strong Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $211, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $211, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.